Description
A topoisomerase II inhibitor; induces relaxation of supercoiled DNA (IC50 = 3.2 µg/ml); induces DNA double-strand breaks in CCRF-CEM cells and cell cycle arrest at the G2 phase in A549 cells in a concentration-dependent manner; inhibits proliferation in a panel of 15 cancer cell lines, including cancer cells resistant to doxorubicin, etoposide, or cisplatin (IC50s = 0.04-1.15 µM); inhibits tumor growth in multidrug-resistant SBC-3/ETP or PC-14/CDDP mouse xenograft models at 20 mg/kg
Formal name: 1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
Synonyms: SNS-595|Voreloxin
Molecular weight: 401.4
CAS: 175414-77-4
Purity: ≥98%
Formulation: A crystalline solid